Positive scans with florbetapir-PET were associated with faster cognitive declines over three years than negative scans in a new study. The findings, which appear in Molecular Psychiatry, support previous data and could assist with the development of new treatments. "If we can accurately identify individuals who are likely to progress compared to individuals who are not likely to progress, that can help drug discovery, even though we don't have a treatment right now to prevent Alzheimer's," said lead author Dr. P. Murali Doraiswamy.

Related Summaries